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Background and Purpose: L-DOPA prolonged treatment leads to disabling motor
complications as dyskinesia that could be decreased by drugs acting on 5-HT1A
receptors. Since the internal segment of the globus pallidus, homologous to the
entopeduncular nucleus in rodents, seems to be involved in the etiopathology
of L-DOPA-induced dyskinesia, we investigated whether the entopeduncular
nucleus is modulated by the 5-HT1A receptor partial and full agonists, buspirone,
and 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT) in control and
6-hydroxydopamine (6-OHDA)-lesioned rats with or without long-term L-DOPA
treatment.
Experimental Approach: Extracellular single-unit electrocorticogram and local field
potential recordings under anaesthesia, immunostaining assays and optogenetic
manipulation coupled to electrophysiological recordings were performed.
Key Results: Systemic buspirone reduced the entopeduncular nucleus firing rate in
the sham animals and burst activity in the 6-OHDA-lesioned rats (with or without
L-DOPA treatment), while local administration reduced entopeduncular nucleus
activity in all the groups, regardless of DA integrity. Systemic 8-OH-DPAT also
induced inhibitory effects only in the sham animals. Effects triggered by buspirone
and 8-OH-DPAT were reversed by the 5-HT1A receptor antagonist, WAY-100635.
Neither buspirone nor 8-OH-DPAT modified the low-frequency oscillatory activity in
the entopeduncular nucleus or its synchronization with the motor cortex. Buspirone
did not alter the response induced by subthalamic nucleus opto-stimulation in the
entopeduncular nucleus.
Conclusion and Implications: Systemic 5-HT1A receptor activation elicits different
effects on the electrophysiological properties of the entopeduncular nucleus
depending on the integrity of the nigrostriatal pathway and it does not alter the rela-
tionship between subthalamic nucleus and entopeduncular nucleus neuron activity.
Abbreviations: 6-OHDA, 6-hydroxydopamine; 8-OH-DPAT, 8-hydroxy-2-(di-n-propylamino)-tetralin; DRD, dorsal raphe dorsal part; DRL, dorsal raphe lateral part; DRV, dorsal raphe ventral part;
DRN, dorsal raphe nucleus; IOD, integrated optical densitometry; L-DOPA, L-3,4-dihydroxyphenylalanine or levodopa; SERT, 5-HT transporter.
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1 | INTRODUCTION
Parkinson's disease is characterized by the selective degeneration
of the nigrostriatal pathway and a concomitant reduction in the
striatal concentration of dopamine. The standard treatment for this
loss of dopamine is the administration of the dopamine precursor,
L-3,4-dihydroxyphenylalanine (L-DOPA). However, prolonged treat-
ment with L-DOPA leads to disabling motor complications such as
dyskinesia. When the L-DOPA treatment losses efficacy or caused
severe motor side effects, many patients move to deep brain stim-
ulation treatment. Stimulation of the subthalamic nucleus or the
internal part of the globus pallidus, which is homologous to the
entopeduncular nucleus in rodents, reduces motor symptoms of
Parkinson's disease and dyskinesia induced by prolonged adminis-
tration of L-DOPA (Olanow et al., 2003; Ramirez-Zamora &
Ostrem, 2018). The subthalamic nucleus and the internal part of
the globus pallidus/entopeduncular nucleus are part of the basal
ganglia nuclei. The subthalamic nucleus is the main excitatory
source while the internal part of the globus pallidus/
entopeduncular nucleus together with the substantia nigra reti-
culata constitutes the output nuclei, which receive a direct input
from the subthalamic nucleus (Dudman & Gerfen, 2015). In
Parkinson's disease patients and experimental models of Parkinson's
disease, the subthalamic nucleus becomes hyperactive (Aristieta
et al., 2012; Breit et al., 2007; Hassin-Baer et al., 2011; Magill
et al., 2001) and exaggerates the excitatory glutamatergic input to
the internal part of the globus pallidus/entopeduncular nucleus,
which also shows hyperactivity (Aristieta et al., 2019; Darbin
et al., 2016; Jin et al., 2016). In addition, dopamine loss enhances
oscillatory activity and synchronization within and between the
basal ganglia nuclei, including the subthalamic nucleus and internal
part of the globus pallidus and the cerebral cortex in distinct
frequency bands. These alterations are related to motor
manifestations in patients with Parkinson's disease (Alonso-Frech
et al., 2006). Overall these observations indicate that pharmacologi-
cal modulation of the electrophysiological properties of the
subthalamic nucleus and the internal part of the globus pallidus/
entopeduncular nucleus could be a good alternative target for
ameliorating Parkinson's disease-related symptoms.
Among the limited number of pharmacological options for
treatment of Parkinson's disease and dyskinesia, drugs acting on the
5-hydroxytryptamine (5-HT; serotonin) system are promising
candidates for treating Parkinson's disease-related symptoms
(Miguelez et al., 2014). Although some findings have indicated that
5-HT1A receptor agonists may reduce anti-parkinsonian L-DOPA
efficacy (Dupre et al., 2007; Iravani et al., 2006), buspirone, which is a
partial agonist of the 5-HT1A receptor, appears to be a potential thera-
peutic agent (Loane & Politis, 2012) according to preclinical and
clinical research of its anti-parkinsonian and anti-dyskinetic properties
(Aristieta et al., 2012; Dekundy et al., 2007; Eskow et al., 2007; Politis
et al., 2014). Furthermore, the efficacy of buspirone is currently
being tested in four placebo-controlled randomized double-blind
clinical trials, one phase III (NCT02617017), two phase II with
co-administration of the 5-HT1B/1D agonist zolmitriptan
(NCT03956979 and NCT04377945) and one phase I as co-therapy
with amantadine (NCT02589340).
We have previously shown that buspirone has various effects
on the subthalamic nucleus and substantia nigra reticulata,
depending on the integrity of the nigrostriatal pathway (Sagarduy
et al., 2016; Vegas-Suárez et al., 2020). In addition, the activities
of entopeduncular nucleus and subthalamic nucleus neurons
were correlated in 6-hydroxydopamine (6-OHDA)-lesioned rats
treated with L-DOPA (Aristieta et al., 2019). Continuing with
this research and to characterize a good target for new
pharmacological treatments for Parkinson's disease, we aimed to
determine the effect of buspirone on entopeduncular nucleus neu-
ron activity, oscillation and synchronization in control and
6-OHDA-lesioned rats with and without prolonged treatment with
L-DOPA and before and during subthalamic nucleus opto-
stimulation.
What is already known
• 5-HT1A receptor agonists are efficacious anti-dyskinetic
drugs.
• The entopeduncular nucleus suffers profound modifica-
tions in 6-OHDA lesioned animals.
What this study adds
• Low doses of buspirone attenuates excessive burst activ-
ity in 6-OHDA lesioned animals.
What is the clinical significance
• Anti-dyskinetic properties of buspirone may partially rely
on its effect on the entopeduncular nucleus.
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2 | METHODS
2.1 | Animals
A total of 87 (11 rats were excluded according to the results
obtained in the cylinder test and the verification of the viral
transfection within the subthalamic nucleus or because in the elec-
trophysiological assay it was not possible to record the neuron
after intravenous drug administration) 8-week male Sprague–
Dawley rats (RRID:MGI:5651135, SGIker facilities, UPV/EHU)
weighing 150–175 g were housed in groups of at least four ani-
mals under standard laboratory (22 ± 1C, 55 ± 5% relative humid-
ity and a 12:12 h light/dark cycle) with ad libitum access to food
and water. Animal studies are reported in compliance with the
ARRIVE guidelines (Percie du Sert et al., 2020) and with the
recommendations made by the British Journal of Pharmacology
(Lilley et al., 2020), and they were approved by the Local Ethical
Committee of the UPV/EHU (Protocol number: CEEA/
M20/2016/176) following the European (2010/63/UE) and Spanish
(RD 53/2013) regulations for the care and use of laboratory
animals. We are aware of the importance of gender inclusion in
preclinical research studies. However, we decided to use only male
rats since 6-OHDA-lesioned rats show some differences between
males and females (Sagarduy et al., 2016). Every effort was made
to minimize animal suffering and to use the minimum number of
animals per group and experiment.
2.2 | Experimental design
Rats were randomly divided into three different experimental
groups:- (1) sham, (2) lesion with 6-OHDA and (3) lesion with
6-OHDA and chronically treated with L-DOPA (6-OHDA/L-DOPA), in
order to be able to assess whether possible observed changes on drug
response were due to the effect of the 6-OHDA lesion or to the
effect of prolonged L-DOPA treatment. For experiments 1 and 2 (elec-
trophysiological and immunohistochemical assays), the rats received
6-OHDA or vehicle injection into the medial forebrain bundle and the
accuracy of the lesion was screened using the cylinder test 3 weeks
later (Figures 1a and 3a). Only animals showing a reduction of striatal
integrated optical densitometry (IOD) of tyrosine hydroxylase
(TH IOD; >80%) were included in the 6-OHDA group. After the
cylinder test, a group of 6-OHDA-lesioned rats received L-DOPA
treatment for 3 weeks and abnormal involuntary movements were
evaluated at the beginning and the end of the treatment. Electrophys-
iological recordings and/or perfusion were performed 6 weeks after
the surgery (sham or 6-OHDA groups) and 24 h after the last dose of
L-DOPA (6-OHDA/L-DOPA group). In experiment 3 (Figure 4a),
optogenetic manipulation of the subthalamic nucleus was performed
4 weeks after the viral injection. Later, the viral transfection in the
subthalamic nucleus was histologically confirmed. All experiments
were analysed under blinded conditions according to British Journal of
Pharmacology guidelines (Kilkenny et al., 2010).
2.3 | Stereotaxic surgery
2.3.1 | 6-OHDA lesion
6-OHDA lesions were carried out as described in detail in one of
our well-established protocols (Aristieta et al., 2019). Thirty minutes
before surgery, the rats were pretreated with desipramine
(25 mgkg−1, i.p.) and pargyline (50 mgkg−1, i.p.) to prevent damage
to the noradrenergic system or degradation of the neurotoxin,
respectively. Next, the rats were deeply anaesthetized using
isoflurane in medical oxygen grade 1l/min 99.5% (4% for
induction and 1.5–2.0% for maintenance) and placed in a stereo-
taxic frame (David Kopf® Instruments) and were allowed to breath
spontaneously. The surgical procedure was performed with
sterilized material and povidone-iodine was applied prior and after
the stereotaxic injection for maintaining aseptic conditions.
6-OHDA (3.5 μgμl−1, in 0.02% ascorbic acid, max volume 4.5 μl)
or vehicle was injected using a 10-μl Hamilton syringe at a rate of
1 μlmin−1 in the co-ordinates of the right medial forebrain bundle
(Paxinos & Watson, 1997): 2.5 μl at the anteroposterior
(AP) (−4.4 mm), mediolateral (ML) (+1.2 mm) and dorsoventral (DV)
(−7.8 mm) relative to bregma with a toothbar set at −2.4 and 2 μl
at AP (−4.0 mm), ML (+0.8 mm) and DV (−8 mm) with a toothbar
at +3.4. After the surgery, animals were allowed to fully recover in
individual cages. This animal model has been widely used and
replicates pathophysiological aspects of Parkinson's disease in
humans (Przedbroski et al., 1995).
2.3.2 | Viral vector injection
The rats were deeply anaesthetized with isoflurane and placed in
the stereotaxic frame as above. The viral vector AAV5-hSyn-hChR2-
(H134R)-EYFP (UNC Vector Core, USA) was delivered with a
calibrated thick-walled micropipette (7087-07, BLAUBRAND®, intra-
Mark, Germany) previously broken to a tip diameter of approximately
40 μm. Pulses (50–150 ms) were applied using Picospritzer™ II
(General Valve Corporation, Fairfield, NJ, USA). A total volume of
500 nl of the viral vector was delivered to the subthalamic nucleus at
the following coordinates (relative to bregma and dura matter): 250 nl
at AP (−3.6 mm), ML (−2.5 mm) and DV (−7.5 mm) and 250 nl at AP
(−3.9 mm), ML (−2.5 mm) and DV (−7.5 mm) (Paxinos &
Watson, 1997). After the surgery, animals were allowed to fully
recover in individual cages.
2.4 | Behavioural tests
2.4.1 | Cylinder test
Three weeks after the 6-OHDA lesion, when the animals had
totally recovered, forelimb asymmetry was evaluated using the
drug-free test cylinder test as previously described (Miguelez
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et al., 2011). Each rat was left in the cylinder until reaching a total
of 20 touches with any of both forelimbs on the walls or a
maximum of 5-min exploration time. The percentage of contralat-
eral forelimb use with respect to the total number of contacts was
calculated. Only animals with an ipsilateral contact percentage of
≥70% were enrolled in this study (Figure S1A).
2.4.2 | Long-term L-DOPA treatment and abnormal
involuntary movement rating
6-OHDA rats received daily treatment with L-DOPA (6 mgkg−1, i.p.)
in combination with peripheral decarboxylase inhibitor benserazide
(12 mgkg−1, i.p.) over 3 weeks. At the beginning and end of
F IGURE 1 Effect of 5-HT1A receptor agonists on entopeduncular neuronal activity in sham and 6-OHDAlesioned rats. (a) Experimental
design of experiment 1. The rats received 6-OHDA or vehicle injection into the medial forebrain bundle and the accuracy of the lesion was
screened using the cylinder test 3 weeks later. Six weeks after the 6-OHDA lesion, entopeduncular nucleus (EP) single-unit extracellular
electrophysiology (E-phy) was performed. (b) Schematic parasagittal section of a rat brain, showing the motor cortex and a glass electrode placed
in the EP for recording single-unit extracellular activity and local field potential (LFP). On the right, an example of an EP neuron action potential.
(c) Examples of the effects of buspirone systemic administration (0.6125–5 mgkg−1, i.v.) on EP neuronal activity in sham and 6-OHDA-lesioned
rats. (d–e) Corresponding dose-effect curves of systemic buspirone (d) and the number of neurons showing burst activity (e) in sham (n = 5),
6-OHDA (n = 6), and 6-OHDA/L-DOPA groups (n = 6). Note that the administration of WAY-100635 reversed the inhibitory effect (grey
shadow). (f) Local administration of buspirone (0.25–2 nmol) induced a dose-dependent inhibitory effect in sham (n = 5), 6-OHDA (n = 5), and
6-OHDA/L-DOPA (n = 5). (g, h) Graphics representing the firing rate (g) and the number of neurons exhibiting burst activity (h) after increasing
doses of 8-OH-DPAT (20–160 μgkg−1, i.v.) in sham (n = 5), 6-OHDA (n = 5) and 6-OHDA/L-DOPA (n = 6). Data are expressed as mean ± S.E.M.
*P < .05 (sham), @P < .05 (6-OHDA/L-DOPA), and $P < .05 (6-OHDA) versus respective basal values (RM two-way ANOVA followed by
Bonferroni's post hoc test) and #P < .05 versus respective baseline (Fisher's exact test for firing pattern)
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the treatment, abnormal involuntary movements were scored
(Figure S1B,C). Each rat was observed for one full minute every 20th
min during the 200-min testing period. The severity of each of the
three subtypes of dyskinetic movements (axial, limb and orolingual)
was rated from 0 to 4 based on the amount of time (0, not present
to 4, continuous). In addition, the amplitude of each dyskinetic move-
ment was rated on a scale from 0 to 4, separately from the locomo-
tive movements (Cenci & Lundblad, 2007). All 6-OHDA/L-DOPA rats
included in this study developed severe abnormal involuntary
movements.
2.5 | Electrophysiological procedures
2.5.1 | Single-unit extracellular recordings of
entopeduncular neurons
Electrophysiological recordings of entopeduncular nucleus neurons
(Figure 1b) were performed 3 weeks after the surgery and 24 h after
the last L-DOPA injection in the 6-OHDA/L-DOPA group (Aristieta
et al., 2019). The rats received one doses of urethane anaesthesia
(1.2 gkg−1, i.p.) and the right jugular vein was cannulated for systemic
drug administration. Next, each rat was placed in a stereotaxic frame
with its head secured in the horizontal plane. The skull was exposed
and a bur-hole was drilled over the co-ordinates of the entopeduncular
nucleus. The recording electrode, consisting of a single barrel glass
micropipette (TW150F-4, World Precision Instruments, UK) filled with
a 2% solution of Pontamine Sky Blue in 0.5% sodium acetate, was
lowered into the right entopeduncular nucleus (AP: −2.3 mm, ML:
−2.5 mm, DV: −7.0 to 8.5 mm, relative to bregma and dura) (Paxinos &
Watson, 1997) and neuronal spikes were digitized using the CED micro
1401 interface and Spike2 software (Cambridge Electronic Design). The
firing rate was recorded for 300 s under basal conditions and 150 s
after each systemic drug dose. These were injected (i.v.) at 1-min inter-
vals, in increasing (×2) doses, so that cumulative dose effect was
analysed. Dose and interval for each drug was selected according to
our previous results (Aristieta et al., 2014; Sagarduy et al., 2016; Vegas-
Suárez et al., 2020). To identify entopeduncular nucleus neurons, we
took the following electrophysiological characteristics into account,
biphasic action potential with a duration of 0.8–0.9 ms and firing rate
between 10 and 20 Hz. For local administration, a calibrated pipette
attached to a recording electrode was filled with 0.25-M buspirone dis-
solved in Dulbecco's buffered solution, as previously described (Vegas-
Suárez et al., 2020). Local buspirone administration was performed by
applying pressure pulses using a Picospritzer™ II. The injected volume
was simultaneously monitored with the movement of the fluid in a
calibrated pipette. Each pulse corresponded to the injection of 2 nl of
solution and 0.25 nmol of buspirone. Every pipette was calibrated so
that each pulse corresponded to the injection of 2 nl of solution
(0.25 nM). Then, two pulses would be 0.5 nM, four pulses would be
1 nM and eight pulses would be 2 nM. Each drug application was
performed when the effect of previous application on the neuronal
firing rate was completely recovered.
2.5.2 | Oscillatory activity and synchronization
The electrocorticogram was simultaneously recorded in these
urethane anesthetized rats via a 1-mm-diameter steel screw on the
right frontal motor cortex (AP: +4.5 mm and ML: −2.5 mm, relative
to bregma) (Paxinos & Watson, 1997). The signal was pre-amplified
(10×), amplified (200×) and bandpass filtered (0.1–1000 Hz) in an
amplifier (Cibertec S.A., model amplifier 63AC). The local field poten-
tial was recorded with the same glass electrode that was used for
the entopeduncular nucleus single-unit extracellular recordings. The
recording signal was pre-amplified (10×) and amplified (10×) in a
high-input impedance amplifier (Cibertec S.A., model amplifier AE-2)
and bandpass filtered (0.1–5000 Hz). This signal was divided into
two different signals in a second amplifier (63AC), namely, the single-
unit and the local field potential signals. In this second amplifier, the
local field potential signal was amplified (10×) and bandpass filtered
(0.1–100 Hz). The discriminated electrocorticogram and the local
field potential activity were digitized and further analysed offline. At
the end of the experiments, a 5-μA cathodal current was passed
through the recording electrode to create a discrete mark of the
Pontamine Sky on the recording site, which would be used to verify
the recording site. Experiments were terminated by transcardiac
perfusion and brain extraction.
2.5.3 | Integrated in vivo optogenetic stimulation
of the subthalamic nucleus coupled to the subthalamic
and entopeduncular electrophysiological recordings
Four weeks after the viral transfection, subthalamic nucleus or
entopeduncular nucleus recordings were performed as described
during subthalamic nucleus optogenetic stimulation (Figure 4a). The
optic bare fibre (200/230 μm core; 1.5-m length, 94063, Plexon,
Texas, USA) was inserted into a modified glass capillary and
lowered into the transfected subthalamic nucleus at a 30 angle to
the horizontal plane (relative to bregma and dura, AP: −8.23 mm,
ML: −2.5 mm and DV: −8.66 mm) using a micromanipulator. The
optic fibre was connected to a PlexBright 465-nm blue LED for an
optogenetic stimulation system (94002-002, Plexon, Texas, USA).
The stimulation was digitally controlled by Spike2 software and dif-
ferent protocols were designed (5.5 mV and 1 s continuous stimu-
lation, 14 mW and 0.5 s continuous stimulation, 14 mW and 25 Hz
trains of stimulation). Previously, the LED intensity was tested and
calibrated using a digital power meter kit (PM100D, Thorlabs, New
Jersey, USA). The intensity was set between 0.5 and 15 mW mea-
sured at the tip of the optic fibre (Figure 4c). Peristimulus time his-
tograms were generated from at least 10 stimulation trials using
1-ms bins to determine the type of response evoked by, as well as
calculate the firing rate before (pre) and during (light-on), the stim-
ulation. The digital protocols were randomized and applied to each
neuron and separated by 5 min. After the electrophysiological
recordings, the verification of viral transfection in the subthalamic
nucleus was performed using confocal microscopy (Zeiss LSM800)
2520 VEGAS-SUAREZ ET AL.
(Figure 4b). Only rats that expressed the appropriate viral transfec-
tion within the subthalamic nucleus and excitation in at least 75%
of the stimulated cells were included in the study. Experiments
were terminated by transcardiac perfusion and brain extraction.
2.5.4 | Analysis of electrophysiological data
Analysis of the electrophysiological parameters was performed off-
line using the Spike2 software (version 7). The firing rate and coeffi-
cient of variation were obtained by applying a script (“meanix.s2s”).
The percentage of neurons demonstrating the burst firing pattern
and burst-related parameters (the number of bursts, mean duration
of burst, spikes per burst, recurrence of burst and intraburst
frequency) were calculated using the script (“surprise.s2s”), which
was based on the Poisson Surprise method (minimum s value = 3
consecutive spikes), within 90 s (Vegas-Suárez et al., 2020). As
described in (Aristieta et al., 2019), local field potential and electro-
corticogram signals were smoothed to 1 ms and the entopeduncular
nucleus action potentials were converted to a series of events.
Next, these events were transformed into a continuous waveform
(1-ms smoothing period) using a custom-made script. Local field
potential and electrocorticogram power spectra and the coherence
between entopeduncular nucleus-spikes and local field potentials, as
well as entopeduncular nucleus-spikes and electrocorticograms and
local field potentials and electrocorticograms, were analysed using
the fast Fourier transform (8192 blocks size) in the low-frequency
range (0–5 Hz) during 90 s applying a script (“coherac90.s2s”). The
AUC of each curve was also calculated. When several neurons were
recorded per animal, the values were averaged and represented as
the only value.
2.6 | Histological procedures and analyses
2.6.1 | Histochemical assays
The immuno-related procedures used comply with the recommenda-
tions made by the British Journal of Pharmacology (Alexander
et al., 2018). Animals were deeply anaesthetized (1.2 gkg−1 urethane
i.p.) and transcardially perfused with saline at 37C followed by 4%
ice-cold paraformaldehyde and 0.2% picric acid prepared in a 0.1-M
phosphate saline buffer. The brains were removed and fixed overnight
in paraformaldehyde. Twenty-four hours later, the brains were trans-
ferred to a 25% sucrose solution until they sank and they were serially
cut in coronal 40-μm sections using a freezing microtome. Brain slices
were kept in a cryoprotectant solution at −20C until further
processing. We performed tyrosine hydroxylase, 5-HT transporter
(SERT) and 5-HT1A receptor immunohistochemistry and neutral
red staining.
Throsine-immunochemistry was used to assess the degree of
dopaminergic denervation in the striatum (Vegas-Suárez
et al., 2020). After endogenous peroxidase inactivation with 3%
H202 and 10% methanol in potassium phosphate-buffered saline
(KPBS), the sections were pre-incubated with 5% normal goat
serum and incubated with primary antibody (rabbit anti-TH,
1:1000, Merck Millipore, Spain) in KPBS/T containing 5% normal
goat serum (NGS) overnight at 22C. In the following days, the
sections were rinsed and incubated for 2 h with the secondary
antibody (biotinylated goat anti-rabbit IgG, 1:200, Vector Laborato-
ries, California, USA) in 2.5% NGS KPBS/T. Thereafter, the sections
were incubated with an avidin-biotin-peroxidase complex (ABC-kit,
PK-6100, Vector Laboratories, California, USA) and peroxidase
activity was visualized using 0.05% 3,3-diaminobenzidine (DAB) and
0.03% H2O2. The sections were mounted onto gelatine-coated
slides, dehydrated in an ascending series of ethanol and
coverslipped in DPX mounting medium.
For another set of slices, we performed SERT and 5-HT1A-
receptor immunohistochemistry following our established protocol
(Vegas-Suárez et al., 2020). We analysed basal ganglia areas such as
the striatum (STR), nucleus accumbens, external globus pallidus,
entopeduncular nucleus, subthalamic nucleus, substantia nigra and
the dorsal, ventral or lateral parts (DRD, DRV and DRL) of the dorsal
raphé nucleus (DRN). Briefly, after endogenous peroxidase inactiva-
tion, the sections containing the basal ganglia and DRN were blocked
with BSA to prevent non-specific antibody binding and incubated with
the primary antibody (rabbit anti-SERT, 1:2500, Immunostar, Hudson,
WI, USA; or rabbit anti-5-HT1A, 1:200, Genetex, California, USA) for
48 h at 22C. Next, the sections were rinsed and incubated with the
secondary biotinylated antibody (donkey anti-rabbit IgG, 1:400,
Jackson Immunoresearch, Stratech Scientific; or goat anti-rabbit IgG,
BA-1000, 1:200, Vector Laboratories, California, USA) for 2 h at 22C.
Sections were rinsed between antibody treatments to remove
unbound and weakly bound antibodies. Later, the sections were
incubated with an ABC-kit and visualized using 0.022% DAB and
0.003% H2O2. Finally, the sections were mounted, dehydrated and
coverslipped.
For the location of the recording site, coronal sections containing
the entopeduncular nucleus were stained with 1% neutral red
(Miguelez et al., 2011), washed, dehydrated and coverslipped. Only
neurons recorded within the entopeduncular nucleus were included in
the study.
2.6.2 | Integrated optical densitometry (IOD) of
the basal ganglia and dorsal raphé nuclei
The IOD of tyrosine hydroxylase (TH) immunoreactivity in the stria-
tum and SERT and 5-HT1A receptor immunoreactivity in the basal
ganglia and DRN were measured as grey levels using NIH-produced
software: (ImageJ win64 Fiji (RRID:SCR_002285; https://imagej.net/
Fiji)). Digital images were obtained using the 20× objective of
an automatic panoramic digital slide scanner (Panoramic MIDI II,
3DHistech, Hungary) and CaseViewer 2.3 (64-bit version) software
(RRID:SCR_017654). The analysis was blinded. Two to four slices
were used per nucleus and the mean IOD was determined by
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subtracting the background defined as a non-immunoreactive zone.
The results (IOD%) were expressed as the ratio of the optical intensi-
ties of the ipsilateral (right) lesioned hemisphere and the intact or
contralateral (left) non-lesioned or intact hemisphere. IOD of the
nuclei in the contralateral hemisphere was similar among the groups,
ruling out any compensatory effect due to the lesion or treatment
(Table S1).
2.7 | Data and statistical analysis
The data and statistics analysis comply with the recommendations
and Declaration of Transparency and Scientific Rigour of British
Journal of Pharmacology (Curtis et al., 2018). Experimental data were
analysed using GraphPad Prism (RRID:SCR_002798, v. 5.01,
GraphPad Software, Inc.). For the basal electrophysiological parame-
ters, SERT and 5-HT1A receptor expressions, ANOVA was applied,
except for the analysis of burst firing, which was conducted using
Fisher's exact test. The effect of systemic or local drug administra-
tion on the electrophysiological parameters was analysed using
repeated measures (RM) two-way ANOVA (group × treatment). For
the systemic administration of drugs, only one cell was recorded per
animal. For local drug administration and optogenetic stimulation,
several neurons were recorded from the same animals, the electro-
physiological parameters values and data were averaged per animal,
so that every animal had one value. For optogenetic experiments,
the paired two-tailed Student's t-test was used to compare
subthalamic nucleus activity before (pre) and during (light-on)
optogenetic stimulation. In addition, the effect of buspirone on
entopeduncular nucleus neurons after and during subthalamic
nucleus optogenetic stimulation was analysed using the repeated
measures (RM) two-way ANOVA. All ANOVAs were followed by
Bonferroni's post hoc tests only if F was significant and there was
no significant variance inhomogeneity. The threshold of statistical
significance was set at P < .05, with corresponding 95% confidence
intervals. All detailed statistical results are shown in Table S1.
Animals were randomized and group size was ≥5 in all cases.
Sometimes groups were unequal for loss of samples during the
recording or the histological verification. Data were presented as
the mean ± SEM for electrophysiological parameters or Box and
Whiskers representing the median and min to max values for
behavioural tests, IOD or optogenetics experiments. Normalization
was used when analysing oscillatory activity and synchronization to
avoid unwanted variation among the groups.
2.8 | Materials
Desipramine hydrochloride, pargyline, L-DOPA, benserazide hydrochlo-
ride and buspirone hydrochloride were obtained from Sigma-Aldrich,
while WAY-100635 maleate and 8-OH-DPAT were obtained from
Tocris-Biogen. These drugs were prepared in 0.9% saline. Urethane and
6-OHDA hydrobromide (Sigma-Aldrich) were dissolved in Milli-Q water
and Milli-Q water containing 0.02% ascorbic acid, respectively. All drug
solutions were prepared on the day of the experiment.
2.9 | Antibodies
As described above, the following primary antibodies were used:
rabbit anti-tyrosine hydroxylase (Cat#AB152, RRIB:AB_3902) for
dopamine fibres, rabbit anti-SERT (Cat#RA24330–100, RRID:
TABLE 1 Entopeduncular nucleus (EP) electrophysiological properties
Parameters Sham (n = 15) 6-OHDA (n = 16) 6-OHDA/L-DOPA (n = 17)
Firing rate (Hz) 17.4 ± 1.7 24.6 ± 2.7 26.7 ± 2.7*
CV (%) 46.8 ± 6.0 55.0 ± 9.4 80.3 ± 10.8*
Neurons exhibiting burst firing pattern (%) 61.5 77.8$ 87.5$
Number of bursts 46.8 ± 13.6 29.4 ± 10.9 46.9 ± 13.9
Duration of burst (ms) 0.6 ± 0.3 0.3 ± 0.1 0.3 ± 0.1
No. of spikes/burst 11.3 ± 2.5 14.1 ± 6.4 14.4 ± 2.2
Recurrence of burst (no. of burst/min) 33.3 ± 9.5 19.6 ± 7.4 24.6 ± 6.2
Intraburst frequency (spike/s) 71.5 ± 14.3 62.6 ± 8.9 66.2 ± 5.1
AUC of the power spectrum of the ECoG (AUC) 0.00052 ± 0.000084 0.00062 ± 0.000067 0.00062 ± 0.000069
AUC of the power spectrum of the LFP (AUC) 0.03 ± 0.003 0.06 ± 0.008* 0.05 ± 0.009
AUC of the coherence of the ECoG/EP spikes (AUC) 0.31 ± 0.04 0.46 ± 0.05 0.56 ± 0.07*
AUC of the coherence of the LFP/EP spikes (AUC) 0.29 ± 0.03 0.45 ± 0.06 0.51 ± 0.05*
AUC of the coherence of the ECoG/LFP spikes (AUC) 1.1 ± 0.11 1.4 ± 0.21 1.0 ± 0.12
Note: Values are expressed as mean ± S.E.M. For the oscillatory and synchronization parameters (power spectra and coherences), AUC values were
calculated. Abbreviations: CV, coefficient of variation; EcoG, electrocorticogram; LFP, local field potential
*P < .05 versus sham (one-way ANOVA followed by Bonferroni's post hoc test).
$P < .05 versus sham (Fisher's exact test).
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AB_1622792) for the SERT and rabbit anti-5-HT1A (Cat#GTX104703,
RRID_AB1241_307) for the 5-HT1A receptor. Subsequently, the
following biotinylated secondary polyclonal antibodies were used:
donkey anti-rabbit IgG, (Cat#711–005-152, RRID:AB_2340) and goat
anti-rabbit IgG (Cat#BA-1000, RRID:AB_2313606).
2.10 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked
to corresponding entries in the IUPHAR/BPS Guide to PHARMACOL-
OGY http://www.guidetopharmacology.org and are permanently
archived in the Concise Guide to PHARMACOLOGY 2019/20
(Alexander et al., 2019).
3 | RESULTS
3.1 | Entopeduncular nucleus neuron activity in
sham and 6-OHDA-lesioned rats
For experiment 1, we recorded and analysed 90 GABAergic neurons
from 53 anaesthetized rats (Figure 1a,b): 26 neurons from the sham
group (n = 15), 27 cells from the 6-OHDA group (n = 16) and 32 neu-
rons from the 6-OHDA/L-DOPA group (n = 17). Post-mortem histo-
logical verification and distinctive electrophysiological properties
(described in the methods) indicated that all recorded cells were
GABAergic neurons located within the entopeduncular nucleus.
Neurons in the 6-OHDA/L-DOPA group fired at higher frequen-
cies and had a significant higher coefficient of variations, while the
F IGURE 2 Effect of systemic administration of buspirone and 8-OH-DPAT on the oscillatory activity and synchronization of the
entopeduncular nucleus and the motor cortex in the low-frequency range (0–5 Hz). (a) Recording track containing entopeduncular nucleus
(EP) spikes, EP-local field potential (LFP) and electrocorticogram (ECoG) from a neuron in the sham group, and posterior analysis of the oscillatory
activity and synchronization represented by the power spectra and coherence plots. (b, c) Effect of increasing doses of systemic buspirone
(0.6125–5 mgkg−1, i.v.) on the percentage of change in AUC of the power spectra relative to baseline values of the ECoG (b) and EP-LFP (c) in
the three experimental groups. (d, e) Same as b and c for 8-OH-DPAT (20–160 μgkg−1, i.v.). (f, g) Effect of acute doses of buspirone on the
percentage of change in the AUC of coherence relative to baseline values between ECoG and EP spikes (f) and EP-LFP and EP spikes (g).
(h, i) Same as f and g for 8-OH-DPAT (20–160 μgkg−1, i.v.). Data are expressed as mean ± S.E.M. *P < .05 versus sham, $P < .05 versus 6-OHDA
and #P < .05 versus baseline (one-way ANOVA or RM two-way ANOVA followed by Bonferroni's post hoc test). Buspirone was tested in five
(sham), six (6-OHDA) and six (6-OHDA/L-DOPA) animals and 8-OH-DPAT in five (sham), five (6-OHDA) and six (6-OHDA/L-DOPA) animals
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number of neurons exhibiting a burst firing pattern significantly
increased in all the 6-OHDA groups, regardless of L-DOPA treatment
(Table 1). Together with the entopeduncular nucleus single-cell
activity, we analysed the oscillatory activity and synchronization by
simultaneously recording the motor cortex electrocorticogram,
entopeduncular nucleus-local field potential and single-unit extracellu-
lar activity in the same groups described above. In agreement with our
previous publication (Aristieta et al., 2019), power spectra analysis
showed low oscillatory activity (0–5 Hz) in the electrocorticogram and
local field potential with a peak near 1 Hz in the three experimental
groups, under basal conditions (Figure 2a). As shown in Table 1, the
AUC values of the electrocorticogram power spectrum were similar in
the three experimental groups, whereas the local field potential AUC
values were significantly higher in the 6-OHDA group. The coherence
analysis showed that synchronization between electrocorticogram
and entopeduncular nucleus spikes, as well as the entopeduncular
nucleus-local field potential and entopeduncular nucleus spikes, was
significantly higher in the 6-OHDA/L-DOPA group,while no difference
was observed in the synchronization between electrocorticogram and
entopeduncular nucleus-local field potential among the studied
groups.
3.2 | Effect of 5-HT1A receptor agonists on
entopeduncular nucleus neuron activity
Systemic administration of buspirone significantly inhibited the firing
rate of entopeduncular nucleus neurons in the sham and 6-OHDA/L-
DOPA groups (Figure 1c,d). However, this inhibition was two to three
times more pronounced in the sham than in the 6-OHDA/L-DOPA
animals (reduction of firing rate with respect to the basal values
obtained after 5 mgkg−1 buspirone for sham: 94.2 ± 2.9% and
6-OHDA/L-DOPA: 39.7 ± 14.5%). The inhibitory effect of systemic
buspirone was lost in the 6-OHDA group. In all cases, this effect was
reversed by systemic administration of the 5-HT1A receptor antago-
nist, WAY-100635 (0.5 mgkg−1, i.v.). To further prove the
F IGURE 3 5-HT1A receptor and SERT immunoreactivity expression in the basal ganglia. (a) Design of experiment. The rats received 6-OHDA
or vehicle injection into the medial forebrain bundle and the accuracy of the lesion was screened using the cylinder test 3 weeks later. Six weeks
after the 6-OHDA lesion, 5-HT1A receptor and SERT immunohistochemistry were performed. (b) Representative coronal sections of the
entopeduncular nucleus with the delimited regions from ipsilateral (IL) and contralateral (CL) hemispheres adapted from Paxinos and
Watson (1997). The example corresponds to a sham animal. (c, d) Box and Whiskers representing the median and min to max values of IOD ratio
of SERT (c) and 5-HT1A receptor immunoreactivity (d), from sham (n = 7), 6-OHDA-lesioned (n = 7) and 6-OHDA/L-DOPA (n = 6) groups. Note a
general reduction in the expression of both markers especially in the 6-OHDA/L-DOPA group. STR: striatum; Acc: nucleus accumbens; GPe:
external globus pallidus; EP: entopeduncular nucleus; STN: subthalamic nucleus; SN: substantia nigra; respectively. *P < .05 versus sham group
(one-way ANOVA followed by Bonferroni's post hoc test)
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contribution of 5-HT1A receptors to the observed effect, WAY-
100635 was applied before buspirone. In this case, the effect of
buspirone in the sham and 6-OHDA/l-DOPA groups was blocked. In
addition, no effect on the firing parameters of entopeduncular nucleus
neurons was observed after WAY-100635 administration (data not
shown). For the firing pattern, buspirone significantly increased the
coefficient of variation only in the sham group. Finally, buspirone
increased the number of bursty neurons in the sham group, while it
slightly decreased this parameter at small doses in the 6-OHDA and
6-OHDA/L-DOPA groups; an increase or no change was observed at
high doses (Figure 1e). Intraburst parameters were similar in all the
groups (Table S2). To further understand the mechanism of buspirone,
we performed local administrations in the entopeduncular nucleus
and measured neuron firing activity. In all the experimental groups
(n = 5 per group), local administration of buspirone (0.25–2 nM) cau-
sed a marked dose-dependent inhibition of neuronal activity with a
maximal significant reduction of the firing rate of approximately 70%
of the basal value (Figure 1f). However, this inhibitory effect was simi-
lar among the groups.
We also investigated the effect of the systemic administration of
the full 5-HT1A receptor agonist 8-OH-DPAT (from 20 μgkg−1 to
160 μgkg−1; i.v.) on entopeduncular nucleus activity in the sham,
6-OHDA-lesioned and 6-OHDA/L-DOPA animals. Drug administra-
tion caused a significant dose-dependent inhibition of the
entopeduncular nucleus neuron firing, which was significant for the
highest doses in the sham and 6-OHDA/L-DOPA groups (Figure 1g).
This effect was twice more pronounced in the sham group than in
the 6-OHDA/L-DOPA group (reduction of firing rate with respect
to the basal values obtained after 80 μgkg−1 8-OH-DPAT for
sham:- 63.7 ± 12.1% and 6-OHDA/L-DOPA:- 27.2 ± 15.9%). The
administration of WAY-100635 (0.5–1 mgkg−1, i.v.) reversed the
inhibitory effect of 8-OH-DPAT. Once again, no inhibitory effect was
observed in the 6-OHDA group. On the other hand, 8-OH-DPAT
administration caused a very mild increase in coefficient of variation
at a dose of 40 μgkg−1 in the 6-OHDA/L-DOPA group. Low doses of
8-OH-DPAT decreased the number of bursty neurons in the three
experimental groups, while high doses increased it; however, the
highest effect was observed in the sham group (Figure 1h). 8-OH-
DPAT administration did not modify the intraburst parameters
(Table S3).
Finally, we investigated the effect of the systemic administration
of buspirone or 8-OH-DPAT on low oscillatory activity and synchroni-
zation. Buspirone administration significantly reduced the AUC of the
electrocorticogram power spectra in the sham group (Figure 2b), while
high doses significantly enhanced the oscillatory activity of local field
potential-entopeduncular nucleus only in the 6-OHDA/L-DOPA group
(Figure 2c). For the effect on synchronization, buspirone did not mod-
ify coherence in any of the analysed situations (Figure 2d); minimal
differences were observed between the 6-OHDA/L-DOPA and
6-OHDA groups for the coherence between the local field potential
and entopeduncular nucleus spikes (Figure 2e). 8-OH-DPAT adminis-
tration did not modify the AUC of the electrocorticogram power spec-
trum (Figure 2f), but it significantly reduced the AUC values of the
local field potential power spectrum in the 6-OHDA/L-DOPA group
(Figure 2g). Coherence analysis revealed that 8-OH-DPAT did not
cause any effect on the synchronization between electrocorticogram
and entopeduncular nucleus or electrocorticogram and local field
potential spikes (Figure 2h). However, it significantly reduced the
AUC values of the coherence between the local field potential and
entopeduncular nucleus spikes in the 6-OHDA/L-DOPA group
F IGURE 4 5-HT1A receptor and SERT immunoreactivity expression in the dorsal raphé nucleus (DRN). (a) Representative coronal sections of
the DRN with the delimited regions from ipsilateral (IL) and contralateral (CL) hemispheres adapted from Paxinos and Watson (1997). The
example corresponds to a sham animal. (c, d) Box and Whiskers representing the median and min to max values of integrated optical
densitometry (IOD) ratio of SERT (c) and 5-HT1A receptor immunoreactivity (d) from sham (n = 7), 6-OHDA-lesioned (n = 7), and 6-OHDA/L-
DOPA (n = 6) groups. Note a general reduction in the expression of both markers especially in the 6-OHDA/L-DOPA group. DRD, DRV and DRL:
dorsal, ventral and lateral regions of the DRN, respectively. *P < .05 versus sham group and $P < .05 versus 6-OHDA group (one-way ANOVA
followed by Bonferroni's post hoc test)
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(Figure 2i). Neither of the tested drugs modified the AUC values of
coherence between the local field potential and electrocorticogram
(data not shown).
3.3 | Integrated optical densitometry for SERT and
5-HT1A receptor immunostaining in the basal ganglia
and dorsal raphé nuclei
To better understand the electrophysiological results and following the
same experimental design, we evaluated SERT and 5-HT1A receptor
immunoreactivities in the basal ganglia and DRN in the three experi-
mental groups (sham, n = 7; 6-OHDA, n = 7; 6-OHDA/L-DOPA, n = 6
animals) (Figure 3a,b). We analysed the immunoreactivities in the dorsal,
ventral and lateral regions of the DRN (DRD, DRV and DRL, respec-
tively) (Figure 4a). In the 6-OHDA group, the average IOD for SERT
immunoreactivity (Figures 3c and 4b) was unmodified, overall, but
slightly reduced in the dorsal striatum or DRD. This reduction was more
consistently observed in most areas measured, striatum, external globus
pallidus, entopeduncular nucleus, DRD, DRV and DRL in the 6-OHDA/
L-DOPA rats. Surprisingly, IOD for SERT immunoreactivity in the
substantia nigra was significantly increased in this latter group.
F IGURE 5 Entopeduncular nucleus (EP) responses after subthalamic nucleus (STN) opto-stimulation and buspirone administration.
(a) Experimental design and a representative parasagittal section of a rat brain showing the viral vector AAV5-hSyn-hChR2(H134R)-EYFP
injection into the STN. Four weeks after the viral injection, the LED fibre was positioned within the STN and STN or EP single-unit extracellular
electrophysiology (E-phy) was performed and analysed during optostimulation. (b) Coronal section showing viral transfection in the STN of the
injected hemisphere. (c) Nonlinear standard curve generated from the calibration of LED illumination at the beginning of the experiments.
(d, e) Effect of light pulse (1 s, ~5.5 mW) on the firing rate of STN neurons (d) and EP neurons (e). Peristimulus histograms were constructed to
show the STN firing rate before, during, and after local optical stimulation with 465-nm blue-light pulses. (f, g) Same as d and e for light pulses of
0.5 s, ~14 mW. (h, i) Same as d and e for trains of stimulations at 25 Hz, during 40 ms and ~14 mW. Note that STN opto-stimulation increased
the EP neuron firing frequency, and buspirone administration did not modify the type of response in the EP induced by STN opto-stimulation.
Box and Whiskers with averaged plots represent the median and min to max values of firing rate value of STN (white) and EP neurons (blue),
n = 6 and 8, respectively. Buspirone (4 mgkg−1, i.p.) administration is highlighted in pink. *P < .05 versus light off (two-tailed paired Student's
t-test or RM two-way ANOVA followed by Bonferroni's post hoc test)
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As for 5-HT1A receptor immunoreactivity (Figure 3d and 4c), a
slight reduction in IOD was found in the striatum and external globus
pallidus of 6-OHDA animals. Similar to SERT immunoreactivity, a
reduction of IOD of 5-HT1A receptor immunoreactivity was observed
in the external globus pallidus, entopeduncular nucleus, subthalamic
nucleus, substantia nigra, DRD, DRV and DRL in the 6-OHDA/L-
DOPA group. The IOD of the immunoreactivity of these two 5-HT
markers was not modified in the nucleus accumbens in any of the
studied situations.
3.4 | Effect of buspirone on opto-stimulation
entopeduncular response
Finally, we carried out opto-stimulation of the subthalamic nucleus
and simultaneous single-unit extracellular recordings of subthalamic
nucleus or entopeduncular nucleus neurons in control animals 4 weeks
after the viral injection. Only rats that showed a stimulatory response
in most of the recorded neurons were included in this study. A total
of 40 subthalamic nucleus neurons were recorded in six animals (five
to nine neurons per animal) before and during opto-stimulation
using three different protocols:- continuous pulses (1-s duration at
~5.5-mW intensity or 0.5-s duration at ~14-mW intensity) and trains
of light pulses (25-Hz frequency, 0.5-s duration at ~14-mW intensity)
(Figure 5d,f,h). For all the protocols, opto-stimulation significantly
excited 35 subthalamic nucleus neurons (87.5%). On average, the sub-
thalamic nucleus neuron firing rate was significantly higher than the
basal value (Figure 5d), almost six times during the first protocol,
almost five times during the second (Figure 5f) and almost three times
during the third (Figure 5h).
Next, we carried out single-unit extracellular recordings of
entopeduncular nucleus neurons from eight animals (three to seven
neurons per animal), while the optic fibre was positioned in the
subthalamic nucleus. subthalamic nucleus opto-stimulation increased
the entopeduncular nucleus firing rate in 26 of the 36 recorded cells
(72.2%) under basal conditions and 19 of the 24 recorded neurons
(79.2%) after buspirone administration. Regardless of the applied proto-
col, entopeduncular nucleus firing activity increased during subthalamic
nucleus stimulation. However, buspirone administration (4 mgkg−1, i.p.)
did not modify the intensity of the response (Figure 5e–i).
4 | DISCUSSION AND CONCLUSIONS
This study extends our previous finding regarding how buspirone
affects basal ganglia nuclei showing that, (1) 5-HT1A receptor activa-
tion elicits different effects on the entopeduncular nucleus electro-
physiological properties depending on the integrity of the nigrostriatal
pathway and the location of the receptor, (2) IODs for SERT and
5-HT1A receptor immunoreactivity are differently regulated by
6-OHDA-lesion along the basal ganglia and DRN and (3), buspirone
does not alter the relationship between subthalamic nucleus and
entopeduncular nucleus neuronal activity.
As we and other authors have previously shown, there was an
increase in burst activity in entopeduncular nucleus neurons from
6-OHDA-lesioned rats and an enhancement in the firing rate after
prolonged treatment with L-DOPA (Aristieta et al., 2019; Jin
et al., 2016). In addition, the effect of systemic buspirone was signifi-
cantly different. Thus, buspirone mainly reduced the firing rate in the
sham group and the burst activity in the 6-OHDA-lesioned groups. A
similar effect on firing rate but not in burst activity was observed for
5-HT1A receptor activation by 8-OH-DPAT. Both firing rate and firing
patterns of neurons from the basal ganglia are altered in animal
models of Parkinson's disease (McGregor & Nelson, 2019). In particu-
lar, the loss of dopamine in the parkinsonian condition leads to an
increase in subthalamic nucleus activity, producing augmented excit-
atory input to the basal ganglia output structures (entopeduncular
nucleus and substantia nigra reticulata) and contributing to the hyper-
activity of these nuclei, which may underlie motor slowing (Alexander
et al., 1986). Buspirone has, however, little effect on low-frequency
oscillation and synchronization and the local effects of 5-HT1A recep-
tor activation were not influenced by dopamine. Since buspirone
shows potent anti-dyskinetic properties in behavioural studies (see
Section 1), the present data together with our previous results
(Sagarduy et al., 2016; Vegas-Suárez et al., 2020) highlight the impor-
tance of firing patterns rather than oscillations in dopamine-depleted
conditions when testing the anti-parkinsonian/anti-dyskinetic effect
of a drug.
Buspirone acts as an antagonist at D2 and D3 dopamine
receptors (Bergman et al., 2013; Dhavalshankh et al., 2007; McMillen
& McDonald, 1983). In addition, all dopamine receptor subtypes are
detected in the entopeduncular nucleus (Lavian et al., 2017; Lavian
et al., 2018) suggesting that buspirone's local effect could be mediated
by blockade ofdopamine receptors. This is however unlikely, since in
that case, buspirone's local administration would have produced no
effect or an increment in neuronal activity. This is based on functional
studies, which have shown that dopamine agonists in vivo and in vitro
reduce the firing activity of entopeduncular nucleus neurons (Boraud
et al., 1998; Lacombe et al., 2009; Lavian et al., 2017; Papa
et al., 1999; Périer et al., 2003; Ruskin et al., 2002). In addition, when
buspirone was applied systemically, the effects we observed were
reversed by 5-HT1A receptor antagonism, suggesting a selective
5-HT1A receptor-mediated effect of this drug. On the other hand, our
results stress that buspirone's effect in the entopeduncular nucleus
involves direct and indirect mechanisms since its local effect is greater
than the systemic effect. This effect is affected by dopamine deple-
tion, probably due to 5-HT neurotransmission changes outside the
entopeduncular nucleus or in the 5-HT input to the entopeduncular
nucleus. Our results show a slight reduction in IOD of SERT immuno-
reactivity in the dorsal striatum after the 6-OHDA-lesion and L-DOPA
treatment in the striatum, external globus pallidus and entopeduncular
nucleus; SERT expression increased in the substantia nigra reticulata.
Published results show that striatal SERT expression in parkinsonian
rats chronically treated with L-DOPA is up-regulated (Rylander
et al., 2010; Tronci et al., 2017), not modified (Prinz et al., 2013) or
even decreased (Nevalainen et al., 2014; Walker et al., 2019). In
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support of our results, reduced SERT-binding has also been found in
the striatum and external globus pallidus from patients with
Parkinson's disease (Albin et al., 2008; Chinaglia et al., 1993; Kish
et al., 2007). Similar to the present results, in our previous study we
found that the IOD for SERT immunoreactivity was unchanged and
increased in the substantia nigra reticulata after 6-OHDA lesions with
and without L-DOPA treatment, respectively (Vegas-Suárez
et al., 2020). On the other hand, we observed a discrete reduction in
the IOD of SERT immunoreactivity in the DRN (the origin of the main
5-HT innervation to the basal ganglia, Benarroch, 2009; Huang
et al., 2019) after the 6-OHDA lesion and L-DOPA treatment, as
observed in patients with early and advanced Parkinson's disease
(Chinaglia et al., 1993; Halliday et al., 1990; Kish et al., 2007; Politis
et al., 2014). The IOD of 5-HT1A receptor immunoreactivity was
slightly but significantly decreased after L-DOPA treatment in the
external globus pallidus, entopeduncular nucleus, subthalamic nucleus
and substantia nigra. Although no changes in mRNA levels and protein
expression were found in the striatum of the 6-OHDA-lesioned rats
(Numan et al., 1995; Radja et al., 1993), 5-HT1A receptor expression is
decreased in the caudate nucleus and cingulate cortex of patients
with Parkinson's disease (Ballanger et al., 2012) but not in the external
globus pallidus and substantia nigra (Huot et al., 2012). Regarding the
different regions of the DRN (DRV, DRD and DRL), we found
decreased IOD of 5-HT1A receptor immunoreactivity in the 6-OHDA/
L-DOPA group, as previously described in rats (Hou et al., 2012), mon-
keys (Frechilla et al., 2001) and patients with Parkinson's disease
(Braak et al., 2003; Doder, Rabiner et al., 2003; Halliday et al., 1990).
Overall, our results suggest that the 5-HT system undergoes degener-
ation after the 6-OHDA lesion, which is worsened by L-DOPA treat-
ment in agreement with the proposed L-DOPA neurotoxic effect on
5-HT neurons (Stansley & Yamamoto, 2014). Both IODs for SERT and
of 5-HT1A receptor immunoreactivity were reduced suggesting that
these receptors are located on 5-HT terminals. However, 5-HT1A
receptors postsynaptically located on the entopeduncular nucleus
seem to be less affected by the 6-OHDA lesions and L-DOPA treat-
ment. This may explain why the systemic 5-HT1A receptor agonist
effect is altered while the local effect remains unchanged. It is impor-
tant to point out that the quantitative estimation of the changes in
SERT and 5-HT1A receptors expression using immunohistochemistry
should be confirmed with truly quantitative methods. such as quanti-
tative autoradiography.
The basal ganglia nuclei, including the subthalamic nucleus,
contain 5-HT1A receptors and receive intense 5-HT innervation
(Miguelez et al., 2014). We used optogenetic stimulation of the sub-
thalamic nucleus to test whether 5-HT1A receptor activation could
alter the subthalamic nucleus-entopeduncular nucleus relationship
when the subthalamic nucleus is hyperactive after dopamine loss
(Aristieta et al., 2012, 2019). First, we found that the direct applica-
tion of light into the subthalamic nucleus previously transfected
with AAV5-hSyn-hChR2-(H134R)-EYFP increased the firing rate of
most but not all subthalamic nucleus recorded neurons. This hetero-
geneity in the subthalamic nucleus neuronal response has been
described by other authors, who attribute it to the activation of
inhibitory neurons within the nucleus that suppresses the activities
of the recorded neurons (Yu et al., 2020). In addition, we observed
that continuous blue-light pulses lasting for 1 s with a 5.5-mW
intensity or 0.5 s with 14 mV caused a higher excitation of
subthalamic nucleus and entopeduncular nucleus neurons than the
trains of 25-Hz pulses with a duration of 0.5 s and intensity of
approximately 14 mW, suggesting the presence of neuron response
saturation, as previously reported (Herman et al., 2014; Lin, 2011;
Lin et al., 2009). Subthalamic nucleus opto-stimulation also
enhanced the activity of most recorded entopeduncular nucleus
neurons and the effect was not related to the intensity or duration
of the subthalamic nucleus stimulation. These results are consistent
with previous findings that showed a significant correlation between
the firing rates of entopeduncular nucleus and subthalamic nucleus
neurons when both nuclei were hyperactive (Aristieta et al., 2019).
There was an increase in entopeduncular nucleus activity following
subthalamic nucleus drug stimulation (Robledo et al., 1988) and an
increase in extracellular glutamate levels in the entopeduncular
nucleus induced by subthalamic nucleus stimulation (Windels
et al., 2000). Note that the present study does not replicate the
conditions of those experiments that apply electrical subthalamic
nucleus-dyskinesia causing an inhibition (Benazzouz et al., 1995) or
excitation of the entopeduncular nucleus (Hashimoto et al., 2003).
In these studies, the effect of subthalamic nucleus-deep brain stimu-
lation may result in the suppression of neuronal activity due to
depolarization blockade.
Next, we investigated whether buspirone modified the effect of
subthalamic nucleus opto-stimulation on entopeduncular nucleus
because buspirone reduces the subthalamic nucleus neuron activity
under control conditions but not after the 6-OHDA lesion when the
subthalamic nucleus is hyperactive (Sagarduy et al., 2016). In line with
this, our results show no effect of buspirone on entopeduncular
nucleus stimulation induced by subthalamic nucleus optogenetic acti-
vation, suggesting that subthalamic nucleus hyperactivity may
dampen buspirone's effect on this basal ganglia output nucleus. It is
important to point out that several studies have shown that high fre-
quency stimulation of the subthalamic nucleus induces inhibition of
raphé 5-HT neuronal activity (Kocabicak et al., 2015; Temel
et al., 2007) and suppression of subthalamic nucleus evoked neuronal
activity (Shehab et al., 2018). However, the low intensity and brief
stimulation we applied caused stimulation of the subthalamic nucleus.
Altogether, our results indicate that when the subthalamic nucleus is
hyperactive due to dopamine loss or opto-stimulation, buspirone has
little effect on the entopeduncular nucleus. Whether this reduction in
the buspirone effect has any clinical relevance is difficult to elucidate.
Interestingly, there is a phase I clinical trial (NCT02589340) that aims
to evaluate the efficacy of combination therapy using buspirone and
amantadine in reducing L-DOPA induced dyskinesia in patients with
Parkinson's disease (McFarthing et al., 2019). Electrophysiological
results have shown that amantadine increases subthalamic nucleus
neuron activity (Allers et al., 2005).
2528 VEGAS-SUAREZ ET AL.
The incidence of Parkinson's disease is progressively increasing
(Tysnes & Storstein, 2017) and there is not yet a way to prevent
L-DOPA-induced dyskinesia (Cenci et al., 2020). Nowadays, one of the
most efficacious treatment when L-DOPA loses efficacy or causes
severe adverse effects is the deep brain stimulation, an invasiveness
technique with several limitations. There is therefore a necessity of
developing new drugs for treating L-DOPA-induced dyskinesia. To do
that, the target and responses that may help to test new drugs in pre-
clinical studies should be characterized first. Our present findings are
in line with those of previous studies (Sagarduy et al., 2016; Vegas-
Suárez et al., 2020), showing that the effect of 5-HT1A receptor
activation is damped by dopamine loss. Furthermore, buspirone in
6-OHDA-lesioned rats mainly affects entopeduncular nucleus-burst
activity and it does not alter subthalamic nucleus control over the
entopeduncular nucleus. Overall, our results provide knowledge about
the 5-HT1A receptor-effects of a potential anti-dyskinetic drug,
buspirone, on the entopeduncular nucleus of an experimental model
of Parkinson's disease prolonged treated with L-DOPA.
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